Pharmacogenetic influences on the response to pharmacological treatment in autism spectrum disorders

Abstract

Aim: About a third of patients with autism spectrum disorder (ASD) receive pharmacological treatment for comorbid symptoms. However, 30%-50% do not respond adequately and/or present severe and long-lasting side effects. Previous studies have reported the influence of variants in genes coding for drug targets on the efficacy and safety of pharmacological treatments, including genetic polymorphisms in dopaminergic and serotonergic systems. However, most studies have focused on the adult population, with relatively few studies in children and adolescents, and no clear biomarkers of response have been reported in these populations. The aim of our study was to identify genetic predictors of drug response in patients with ASD. This information may be used to personalise pharmacological treatment and improve the efficacy and safety of psychotropic drugs in patients with ASD.

Methods: Genetic variants in dopaminergic and serotonergic drug targets (SLC6A3, DRD2, DRDRD3, DRD4, HTR2A, and HTR2C) and in other genes previously associated with treatment efficacy and/or induced side effects (ANKK1, BDNF, COMT, and HTR1A) were investigated in 176 children and adolescents diagnosed with ASD and undergoing pharmacological treatment.

Results: A SLC6A3 genetic variant was associated with response to methylphenidate in our ASD cohort, whereas HTR2A and HTR2C allele and haplotype distributions were associated with adverse reactions such as somnolence, mood alterations, and BMI. ANKK1, COMT, and BDNF genetic variants were mainly associated with treatment side effects.

Conclusion: If confirmed, these genetic variants may be used as predictors of clinical outcome and help to personalise pharmacological treatments in patients with ASD.

Keywords

Autism / pharmacogenetics / methylphenidate / antipsychotic / antidepressant / dopamine / serotonin

References

[1] BrownJT,CookEH.Pharmacogenomics of autism spectrum disorder.Pharmacogenomics2017;18:403-14

[2] DodsworthT,ProcyshynRM,HonerWG.A systematic review of the effects of CYP2D6 phenotypes on risperidone treatment in children and adolescents.Child Adolesc Psychiatry Ment Health2018;12:37 PMCID:PMC6048722

[3] ArranzMJ,SamperizBA.Pharmacogenetics of the efficacy of antipsychotic drugs in schizophrenia. In: Rybakowski JK, Serretti A, editors. Genetic influences on response to drug treatment for major psychiatric disorders. Cham: Springer International Publishing; 2016. p. 1-20.

[4] FabbriC.Pharmacogenetics of the efficacy and side effects of antidepressant drugs. In: Rybakowski JK, Serretti A, editors. Genetic influences on response to drug treatment for major psychiatric disorders. Cham: Springer International Publishing; 2016. p. 39-54.

[5] FabbriC,MössnerR.Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response.World J Biol Psychiatry2017;18:5-28

[6] PagerolsM,Sánchez-MoraC.Pharmacogenetics of methylphenidate response and tolerability in attention-deficit/hyperactivity disorder.Pharmacogenomics J2017;17:98-104

[7] JoensenB,AagaardL.Specific genes associated with adverse events of methylphenidate use in the pediatric population: a systematic literature review.J Res Pharm Pract2017;6:65-72 PMCID:PMC5463551

[8] Purper-OuakilD.[Use of psychotropic drugs in children].Arch Pediatr2008;15:1834-6

[9] Gomez-SanchezCI,Riveiro-AlvarezR.Pharmacogenetics of methylphenidate in childhood attention-deficit/hyperactivity disorder: long-term effects.Sci Rep2017;7:10391 PMCID:PMC5583388

[10] NaumovaD,SenguptaSM.DRD4 exon 3 genotype and ADHD: Randomised pharmacodynamic investigation of treatment response to methylphenidate.World J Biol Psychiatry2019;20:486-95

[11] MyerNM,FaraoneSV.Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD.Mol Psychiatry2018;23:1929-36 PMCID:PMC7039663

[12] FageeraW,FortierMÈ.Association between COMT methylation and response to treatment in children with ADHD.J Psychiatr Res2021;135:86-93

[13] BonviciniC,ScassellatiC.Attention-deficit hyperactivity disorder in adults: A systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies.Mol Psychiatry2016;21:872-84 PMCID:PMC5414093

[14] McCrackenJT,PoseyDJ.Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders.Pharmacogenomics J2014;14:295-302 PMCID:PMC4034115

[15] CorreiaCT,SantosPE.Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions.Pharmacogenomics J2010;10:418-30

[16] PurcellS,Todd-BrownK.PLINK: a tool set for whole-genome association and population-based linkage analyses.Am J Hum Genet2007;81:559-75 PMCID:PMC1950838

[17] GadowKD,PerlmanG.Association of dopamine gene variants, emotion dysregulation and ADHD in autism spectrum disorder.Res Dev Disabil2014;35:1658-65 PMCID:PMC4084560

[18] FroehlichTE,NickTG.Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder.J Am Acad Child Adolesc Psychiatry2011;50:1129-1139.e2 PMCID:PMC3225067

[19] AkayAP,GüneySA.Serum brain-derived neurotrophic factor levels in treatment-naïve boys with attention-deficit/hyperactivity disorder treated with methylphenidate: an 8-week, observational pretest-posttest study.Eur Child Adolesc Psychiatry2018;27:127-35

[20] WinsbergBG.Association of the dopamine transporter gene (DAT1) with poor methylphenidate response.J Am Acad Child Adolesc Psychiatry1999;38:1474-7

[21] NuntamoolN,VanwongN.Pharmacogenomics and efficacy of risperidone long-term treatment in Thai autistic children and adolescents.Basic Clin Pharmacol Toxicol2017;121:316-24

[22] TharoorH,ToddRD.Association of dopamine, serotonin, and nicotinic gene polymorphisms with methylphenidate response in ADHD.Am J Med Genet B Neuropsychiatr Genet2008;147B:527-30

[23] JiHS,ParkWS.No association between the response to methylphenidate and DRD4 gene polymorphism in korean attention deficit hyperactivity disorder: a case control study.Clin Psychopharmacol Neurosci2013;11:13-7 PMCID:PMC3650292

[24] ZeniCP,PolanczykGV.No significant association between response to methylphenidate and genes of the dopaminergic and serotonergic systems in a sample of Brazilian children with attention-deficit/hyperactivity disorder.Am J Med Genet B Neuropsychiatr Genet2007;144B:391-4

[25] SukasemC,SrisawasdiP.Pharmacogenetics of risperidone-induced insulin resistance in children and adolescents with autism spectrum disorder.Basic Clin Pharmacol Toxicol2018;123:42-50

[26] OblakA,BlattGJ.Reduced serotonin receptor subtypes in a limbic and a neocortical region in autism.Autism Res2013;6:571-83 PMCID:PMC3859849

[27] ParkYH,KwonHJ.Association between HTR1A gene polymorphisms and attention deficit hyperactivity disorder in Korean children.Genet Test Mol Biomarkers2013;17:178-82

[28] AbdelrahmanHM,AlghobashyAA.Association of 5-HT2A receptor gene polymorphisms with gastrointestinal disorders in Egyptian children with autistic disorder.Res Dev Disabil2015;36C:485-90

[29] SmithRM,HansenE,HermanGE.Family-based clinical associations and functional characterization of the serotonin 2A receptor gene (HTR2A) in autism spectrum disorder.Autism Res2014;7:459-67 PMCID:PMC4134733

[30] HervásA,RomarísP.The involvement of serotonin polymorphisms in autistic spectrum symptomatology.Psychiatr Genet2014;24:158-63

[31] GadowKD,PinsonneaultJK.Serotonin 2A receptor gene (HTR2A) regulatory variants: possible association with severity of depression symptoms in children with autism spectrum disorder.Cogn Behav Neurol2014;27:107-16

[32] ValenciaAV,SampedroME.[Evidence for association and epistasis between the genetic markers SLC6A4 and HTR2A in autism etiology].Biomedica2012;32:585-601

[33] Al-JanabiI,BlakemoreAI.Association study of serotonergic gene variants with antipsychotic-induced adverse reactions.Psychiatr Genet2009;19:305-11

[34] ArranzMJ,HernándezMH.Pharmacogenetics of antipsychotics: clinical utility and implementation.Behav Brain Res2021;401:113058

[35] TakekitaY,KatoM.HTR1A polymorphisms and clinical efficacy of antipsychotic drug treatment in schizophrenia: a meta-analysis.Int J Neuropsychopharmacol2016;19:pyv125 PMCID:PMC4886666

[36] ZhaoX,LiJ.Association between the 5-HT1A receptor gene polymorphism (rs6295) and antidepressants: a meta-analysis.Int Clin Psychopharmacol2012;27:314-20

[37] HazelwoodLA.His452Tyr polymorphism in the human 5-HT2A receptor destabilizes the signaling conformation. Mol Pharmacol. 2004;66:1293-300.

[38] LiP,LinWY.Genetic association analysis of 30 genes related to obesity in a European American population.Int J Obes (Lond)2014;38:724-9 PMCID:PMC3909018

[39] ZhaoX,SunYH.Association of HTR2A T102C and A-1438G polymorphisms with susceptibility to major depressive disorder: a meta-analysis.Neurol Sci2014;35:1857-66

[40] ReynoldsGP,KirkSL.The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics.J Psychopharmacol2006;20:15-8

[41] SaghazadehA.Brain-derived neurotrophic factor levels in autism: a systematic review and meta-analysis.J Autism Dev Disord2017;47:1018-29

[42] AmiriA,KoushaM.Changes in plasma brain-derived neurotrophic factor (BDNF) levels induced by methylphenidate in children with Attention deficit-hyperactivity disorder (ADHD).Prog Neuropsychopharmacol Biol Psychiatry2013;47:20-4

[43] YooHJ,ChoIH,KimSA.Polymorphisms of BDNF gene and autism spectrum disorders: family based association study with korean trios.Psychiatry Investig2014;11:319-24 PMCID:PMC4124192

[44] KimBN,KimJW.Val/Val genotype of brain-derived neurotrophic factor (BDNF) Val⁶⁶Met polymorphism is associated with a better response to OROS-MPH in Korean ADHD children.Int J Neuropsychopharmacol2011;14:1399-410

[45] ManchiaM.Targeting aggression in severe mental illness: The predictive role of genetic, epigenetic, and metabolomic markers.Prog Neuropsychopharmacol Biol Psychiatry2017;77:32-41

[46] ParkS,KimBN,YooHJ.Catechol-O-methyltransferase Val158-Met polymorphism and a response of hyperactive-impulsive symptoms to methylphenidate: a replication study from South Korea.J Psychopharmacol2014;28:671-6

[47] Salatino-OliveiraA,ZeniC.Catechol-O-methyltransferase valine158methionine polymorphism moderates methylphenidate effects on oppositional symptoms in boys with attention-deficit/hyperactivity disorder.Biol Psychiatry2011;70:216-21

[48] McGoughJJ,LooSK.A candidate gene analysis of methylphenidate response in attention-deficit/hyperactivity disorder.J Am Acad Child Adolesc Psychiatry2009;48:1155-64 PMCID:PMC2888980

[49] KereszturiE,BognarE.Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children.Am J Med Genet B Neuropsychiatr Genet2008;147B:1431-5

[50] CheonKA,ChoDY.Association of the catechol-O-methyltransferase polymorphism with methylphenidate response in a classroom setting in children with attention-deficit hyperactivity disorder.Int Clin Psychopharmacol2008;23:291-8

[51] BruxelEM,GenroJP.Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidate.Pharmacogenomics J2013;13:476-80

[52] NemodaZ,TarnokZ,Sasvari-SzekelyM.Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD.Neuropharmacology2009;57:731-3

[53] ThümmlerS,DavidR.Pharmacoresistant severe mental health disorders in children and adolescents: functional abnormalities of cytochrome P450 2D6.Front Psychiatry2018;9:2 PMCID:PMC5810290